| Autor: |
Megan K. Yee, C. Michael Gibson, Tarek Nafee, Mathieu Kerneis, Yazan Daaboul, Serge Korjian, Gerald Chi, Fahad AlKhalfan, Adrian F. Hernandez, Russell D. Hull, Alexander T. Cohen, Samuel Z. Goldhaber |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
TH Open, Vol 03, Iss 02, Pp e103-e108 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2512-9465 |
| DOI: |
10.1055/s-0039-1685496 |
| Popis: |
Abstract Background Among medically ill patients treated with thromboprophylaxis, betrixaban was not associated with an increase in major bleeding compared with enoxaparin, but an increase in clinically relevant non-major (CRNM) bleeding was observed. The aim of this analysis is to describe the severity and clinical consequences of major and CRNM bleeding in the APEX trial. Methods The APEX trial randomized 7,513 hospitalized acutely ill medical patients to receive either enoxaparin for 6 to 14 days or betrixaban for 35 to 42 days. Subjects receiving a concomitant strong p-glycoprotein inhibitor or with creatinine clearance |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
